Analysis of global non-melanoma skin cancer incidence and mortality: Thierry Passeron

Touch Medical Media coverage of data presented at EADV 2023:

Non-melanoma skin cancer (NMSC) is responsible for a higher worldwide mortality rate compared to melanoma, a more severe type of skin cancer. A comprehensive analysis of global skin cancer incidence and mortality assessed global skin cancer epidemiology, emphasizing incidence, mortality, risk profiles, and dermatologist density’s impact. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the key outcomes and the likely impact the findings will have on clinical practice.

The abstract ‘A comprehensive analysis of global skin cancer incidence and mortality with a focus on dermatologist density and population risk factors‘ (Abstract N°: P1519) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.

Questions

1. What is the global burden of non-melanoma skin cancer? (0:11)
2. What were the key outcomes from your study of WHO International Agency for Research on Cancer? (0:38)
3. What impact will these findings have on clinical practice? (1:58)

Disclosures: Thierry Passeron has been a consultant for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma; received grant/research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, Lilly; and has received honorarium from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.

Filmed in coverage of the EADV Annual Meeting.

This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Click here for more content on vitiligo and pigmentation disorders & for further EADV 2023 highlights visit here.